---
title: "SK Biopharm's Q4 Attributable Income Soars Nearly 28-Fold to KRW190 Billion"
date: "2025-02-10 19:04:44"
summary: "SK Biopharmaceuticals posted a net income attributable to shareholders of 190.1 billion won in the fourth quarter of 2024, up 2,712.4% from 6.8 billion won a year earlier. Sales jumped 28.6% year over year to 163.03 billion won from 126.8 billion won, according to a Friday filing. Shares of SK..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

SK Biopharmaceuticals posted a net income attributable to shareholders of 190.1 billion won in the fourth quarter of 2024, up 2,712.4% from 6.8 billion won a year earlier.

Sales jumped 28.6% year over year to 163.03 billion won from 126.8 billion won, according to a Friday filing.

Shares of SK Biopharmaceuticals fell nearly 3% at market close on Monday.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250210:G2465727:0/)
